Literature DB >> 8175166

Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-beta 1 expression.

A D Everett1, A Tufro-McReddie, A Fisher, R A Gomez.   

Abstract

The role of angiotensin II via the angiotensin type 1 or type 2 receptor in the development of cardiac hypertrophy was determined in adult male Sprague-Dawley rats subjected to coarctation of the abdominal aorta. Five groups of animals were studied: coarctation, coarctation plus DuP 753, coarctation plus PD 123319, sham plus DuP 753, or sham operation. Type 1 receptor blockade was accomplished with DuP 753 given in the drinking water and type 2 blockade with PD 123319 delivered by osmotic minipumps beginning with the day of surgery until 72 hours after aortic coarctation. Mean carotid blood pressures and the carotid-femoral artery blood pressure gradients were not different among coarctation, coarctation plus DuP 753, and coarctation plus PD 123319 animals. However, ratios of heart weight to body weight were higher in coarctation (4.95 +/- 0.8) or coarctation plus PD 123319 (4.52 +/- 0.5) than in sham animals (3.6 +/- 0.4; P < .005 and .05, respectively). In coarctation plus DuP 753-treated animals heart weight-body weight ratios were not different from sham or sham plus DuP 753 animals (3.9 +/- 0.4 versus 3.6 +/- 0.4 or 3.3 +/- 0.08, respectively). Type 1 receptor mRNA levels were significantly increased in the coarctation group, with the highest levels in the coarctation plus DuP 753 and sham plus DuP 753 groups. To determine whether growth factors were involved in the hypertrophic process, we measured transforming growth factor-beta 1 mRNA levels. Northern analysis demonstrated a twofold increase in coarctation animals compared with sham or coarctation plus DuP 753-treated animals.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8175166     DOI: 10.1161/01.hyp.23.5.587

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  34 in total

1.  Angiotensin II receptor expression and inhibition in the chronically hypoxic rat lung.

Authors:  L Zhao; R al-Tubuly; A Sebkhi; A A Owji; D J Nunez; M R Wilkins
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

2.  Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents.

Authors:  Chih-Chang Wei; Naoki Hase; Yukiko Inoue; Eddie W Bradley; Eiji Yahiro; Ming Li; Nawazish Naqvi; Pamela C Powell; Ke Shi; Yoshimasa Takahashi; Keijiro Saku; Hidenori Urata; Louis J Dell'italia; Ahsan Husain
Journal:  J Clin Invest       Date:  2010-03-24       Impact factor: 14.808

Review 3.  Molecular biology of angiotensin receptors and their role in human cardiovascular disease.

Authors:  V Regitz-Zagrosek; M Neuss; J Holzmeister; C Warnecke; E Fleck
Journal:  J Mol Med (Berl)       Date:  1996-05       Impact factor: 4.599

4.  TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II.

Authors:  Jo El J Schultz; Sandra A Witt; Betty J Glascock; Michelle L Nieman; Peter J Reiser; Stacey L Nix; Thomas R Kimball; Thomas Doetschman
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

5.  Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors.

Authors:  Y H Liu; X P Yang; V G Sharov; O Nass; H N Sabbah; E Peterson; O A Carretero
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

6.  Overexpression of angiotensin AT1 receptor transgene in the mouse myocardium produces a lethal phenotype associated with myocyte hyperplasia and heart block.

Authors:  L Hein; M E Stevens; G S Barsh; R E Pratt; B K Kobilka; V J Dzau
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

7.  Editorial Commentary: Understanding Marfan syndrome, or "how not to invent the light bulb".

Authors:  Jeffrey A Jones
Journal:  Trends Cardiovasc Med       Date:  2016-02-23       Impact factor: 6.677

8.  Angiotensin II stimulates hyperplasia but not hypertrophy in immature ovine cardiomyocytes.

Authors:  N C Sundgren; G D Giraud; P J S Stork; J G Maylie; K L Thornburg
Journal:  J Physiol       Date:  2003-03-07       Impact factor: 5.182

9.  Atenolol versus losartan in children and young adults with Marfan's syndrome.

Authors:  Ronald V Lacro; Harry C Dietz; Lynn A Sleeper; Anji T Yetman; Timothy J Bradley; Steven D Colan; Gail D Pearson; E Seda Selamet Tierney; Jami C Levine; Andrew M Atz; D Woodrow Benson; Alan C Braverman; Shan Chen; Julie De Backer; Bruce D Gelb; Paul D Grossfeld; Gloria L Klein; Wyman W Lai; Aimee Liou; Bart L Loeys; Larry W Markham; Aaron K Olson; Stephen M Paridon; Victoria L Pemberton; Mary Ella Pierpont; Reed E Pyeritz; Elizabeth Radojewski; Mary J Roman; Angela M Sharkey; Mario P Stylianou; Stephanie Burns Wechsler; Luciana T Young; Lynn Mahony
Journal:  N Engl J Med       Date:  2014-11-18       Impact factor: 91.245

10.  Development of pressure overload induced cardiac hypertrophy is unaffected by long-term treatment with losartan.

Authors:  M Turcani; H Rupp
Journal:  Mol Cell Biochem       Date:  1998-11       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.